Syndromic Osteosarcoma, Does It Carry a Poor Prognosis? A Case Series Report with Literature Review
The goal of our research was to look into the relationship between osteosarcoma and syndromic traits, as well as the potential effects on osteosarcoma prognosis. Osteosarcoma is a mesenchymal cell-derived malignancy. Children between the ages of 10 and 14 are most commonly affected by osteosarcoma, which is usually caused by a primary cause. Some genetic diseases have been linked to an increased risk of osteosarcoma. This study included a case series report of six instances with diverse syndromes, and we retrospectively analysed the prognosis of the cases. The data was obtained at Jordan’s King Hussein Cancer Center from January 2003 to December 2011. During the study period, 69 patients were diagnosed with osteosarcoma, with 6 of them having associated syndromes, accounting for 8.7% of all cases. Rothmund-Thomson Syndrome, Osteogenesis Imperfecta, Diamond-Blackfan Anemia, Osteopoikilosis, and Cockayne Syndrome were among the syndromes discovered. In 14 of the 63 non-syndromic patients, follow-up was lost. In the remaining 49 patients, 34 (69.3%) were living and 15 (30.6%) died, while one was lost for follow-up, just one stayed alive (20%), and four died among the syndromic patients (80 percent ). Because a relationship with a higher mortality rate was discovered (p0.05), statistical analysis revealed that syndromic patients had a worse prognosis than non-syndromic individuals. Our findings suggest that syndromic patients have a worse prognosis, and that osteosarcoma should be considered during differential diagnosis and follow-up for their syndromes. Early detection and treatment may help to enhance the patient’s outcome and survival.
Author(S) Details
Abdulqader Al-Hebshi
Hematology & Oncology Division, Department of Pediatric , Prince Mohammad bin Abdulaziz Hospital (PMBAH), Ministry of National Guard-Health Affairs (MNG-HA), Medina, Saudi Arabia.
Taleb Ismael
Hematology Oncology Division, Department of Pediatric, King Hussein Cancer Center (KHCC), Amman, Jordan.
View Book:- https://stm.bookpi.org/RDMMR-V13/article/view/5025
